Pfizer to Ship Half as Many Coronavirus Vaccine Doses as Originally Planned in Initial Phase

The supply of the coronavirus vaccine developed by Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) will be significantly lower than first anticipated -- at least in the initial stages of distribution. Pfizer said that it will likely ship only half of the doses it originally planned, due to a set of challenges it wasn't able to surmount. Addressing two of these, an unnamed company spokeswoman, quoted in The Wall Street Journal, said that "Scaling up the raw material supply chain took longer than expected, and it's important to highlight that the outcome of the clinical trial was somewhat later than the initial projection."